Biophan Technologies to Present Today at NanoCommerce 2003 Conference; CEO to Discuss Company's Significant Potential Markets for Nanomagnetic Thin-Film Coatings.

Business Editors/Health/Medical Writers

NanoCommerce 2003 Conference

BIOWIRE2K

ROCHESTER, N.Y.--(BUSINESS WIRE)--Dec. 9, 2003

Biophan Technologies, Inc. (OTCBB: BIPH), an innovator, developer and marketer of cutting-edge advanced biomedical technologies, today announced that Michael Weiner, Chief Executive Officer, has been selected to speak at the NanoCommerce 2003 conference which commences today. Co-sponsored by the U.S. Department of Commerce, the two-day, Chicago-based conference is designed to provide a national platform for organizations to create or expand major commercial markets for cutting-edge technology, such as Biophan's portfolio of next-generation biomedical technologies.

Weiner's presentation will highlight emerging nanomagnetic technologies, their promising commercial applications in diagnostics and medical devices, and the highly articulated strategic plan Biophan is taking to develop the technology, including exciting new uses being announced at the conference.

"It is our firm opinion that the secondary application of this nanomagnetic particle technology can represent a major new area of opportunity for us--and may become one of the core drivers to our ongoing growth," stated Weiner. "MRI and other diagnostic imaging methods can be greatly improved by the use of contrast agents that preferentially bind to tissues of diagnostic interest, providing numerous substantial improvements. Nanomagnetic particles hold the promise of improved performance in terms of signal intensity and the use of multiple markers which, when fully monetized, can result in significant benefit to Biophan-and ultimately our shareholders," Weiner added.

Additional information on INFOCAST's NanoCommerce 2003 conference can be found at: www.nanocommerce2003.com.

About Biophan Technologies, Inc.

Biophan Technologies, Inc. develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools-safe and compatible with magnetic resonance imaging (MRI) equipment and other sources of powerful magnetism or radio frequency signals. Committed to growth through innovation and developmental leadership, Biophan's management holds exclusive licenses for three issued U.S. patents and has filed 51 related patents that will help establish Biophan products as the standard of care in each of their markets.

Cautionary Statement Regarding Forward-Looking Statements 

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.